Sherene Loi
#104,095
Most Influential Person Now
Consultant oncologist and researcher
Sherene Loi's AcademicInfluence.com Rankings
Sherene Loimedical Degrees
Medical
#1551
World Rank
#1901
Historical Rank
Oncology
#72
World Rank
#76
Historical Rank
Sherene Loiphilosophy Degrees
Philosophy
#4943
World Rank
#7630
Historical Rank
Logic
#2301
World Rank
#3265
Historical Rank
Download Badge
Medical Philosophy
Sherene Loi's Degrees
- PhD Oncology University of Melbourne
Why Is Sherene Loi Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sherene Loi is an Australian oncologist. She is the 2021 winner of the Australian Prime Ministers Prize for Science, in the category of Frank Fenner Prize for Life Scientist of the Year. Loi is Head of Translational Breast Cancer Research, within the Peter Macallum Cancer Centre. Loi's research has advanced understanding into breast cancer, developing and implementing an immune system biomarker. This biomarker will enable improved management for people with advanced cancer. This biomarker is now part of routine pathology reporting across many countries and also is included in the World Health Organization Classification of Tumours .
Sherene Loi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. (2006) (1930)
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
- Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer (2018) (1567)
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. (2013) (1281)
- Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. (2006) (1199)
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. (2016) (1176)
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) (1032)
- Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. (2019) (938)
- Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. (2007) (814)
- Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. (2015) (800)
- CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013) (712)
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018) (674)
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. (2015) (634)
- Consensus guidelines for the detection of immunogenic cell death (2014) (634)
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (616)
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. (2014) (612)
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic (2016) (602)
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. (2017) (597)
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020) (595)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (584)
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis (2018) (569)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (504)
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (2016) (503)
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (500)
- Clinical application of the 70-gene profile: the MINDACT trial. (2008) (468)
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study (2019) (464)
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. (2015) (456)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy (2011) (400)
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape (2012) (395)
- Dissecting the heterogeneity of triple-negative breast cancer. (2012) (393)
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2015) (385)
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study (2019) (368)
- Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen (2008) (368)
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer (2013) (364)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) (345)
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer (2010) (340)
- Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer (2005) (317)
- Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. (2013) (315)
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling (2012) (308)
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. (2018) (305)
- A three-gene model to robustly identify breast cancer molecular subtypes. (2012) (303)
- Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. (2011) (293)
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. (2020) (287)
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. (2019) (281)
- Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. (2017) (270)
- Precision medicine for metastatic breast cancer—limitations and solutions (2015) (262)
- Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial (2006) (253)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020) (233)
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses (2015) (232)
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (2018) (224)
- PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (2014) (222)
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy (2017) (217)
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021) (215)
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. (2017) (215)
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer (2017) (213)
- Intratumoral heterogeneity in cancer progression and response to immunotherapy (2021) (210)
- Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. (2012) (205)
- PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. (2015) (204)
- Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. (2020) (196)
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade (2019) (193)
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group (2016) (189)
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019) (188)
- Relevance of tumor-infiltrating lymphocytes in breast cancer (2015) (182)
- Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer (2012) (176)
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). (2016) (176)
- The genomic landscape of breast cancer and its interaction with host immunity. (2016) (167)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (160)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
- RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (140)
- LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 (2017) (137)
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer (2013) (133)
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. (2020) (132)
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. (2020) (129)
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial (2016) (128)
- Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (2017) (127)
- Triple-negative breast cancer: recent treatment advances (2019) (126)
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. (2013) (124)
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. (2021) (122)
- Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. (2017) (120)
- Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021) (117)
- Tissue-resident memory T cells in breast cancer control and immunotherapy responses (2020) (117)
- Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial (2017) (114)
- Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. (2016) (113)
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice (2020) (108)
- Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. (2007) (107)
- Pertuzumab: new hope for patients with HER2-positive breast cancer. (2013) (107)
- Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2017) (105)
- The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” (2016) (104)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2016) (100)
- Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses (2018) (100)
- Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients (2018) (100)
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy (2013) (100)
- Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer (2008) (98)
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. (2017) (97)
- PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data (2014) (96)
- Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. (2018) (96)
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. (2017) (95)
- Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 (2019) (95)
- Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). (2017) (92)
- CD 4 + follicular helper T cell infiltration predicts breast cancer survival (2013) (91)
- Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis (2016) (89)
- Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer (2017) (88)
- Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context (2010) (86)
- Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. (2013) (85)
- Identification of Novel Ras-Cooperating Oncogenes in Drosophila melanogaster: A RhoGEF/Rho-Family/JNK Pathway Is a Central Driver of Tumorigenesis (2011) (83)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (83)
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2013) (82)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (82)
- Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). (2017) (78)
- Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions (2017) (76)
- Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. (2017) (75)
- Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (73)
- Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis (2019) (70)
- A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. (2012) (69)
- Checkpoint blockade in the treatment of breast cancer: current status and future directions (2018) (69)
- Immune Infiltration in Invasive Lobular Breast Cancer (2018) (68)
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (67)
- The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast (2016) (67)
- CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. (2017) (66)
- Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. (2016) (66)
- Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. (2018) (66)
- Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer (2009) (64)
- Beyond trastuzumab: new treatment options for HER2-positive breast cancer. (2011) (64)
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer (2021) (62)
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. (2019) (62)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. (2022) (59)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (2019) (57)
- Biology of breast cancer during pregnancy using genomic profiling. (2014) (55)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (54)
- A community-based model of rapid autopsy in end-stage cancer patients (2016) (54)
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy (2019) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial (2016) (54)
- Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) (2018) (53)
- A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. (2017) (53)
- The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. (2021) (51)
- Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment (2012) (51)
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2−) breast cancers? (2012) (50)
- LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC (2021) (50)
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. (2018) (50)
- Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection (2010) (50)
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. (2019) (50)
- Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy (2016) (50)
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer (2015) (49)
- Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells (2018) (48)
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer (2018) (48)
- Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC (2017) (47)
- Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (47)
- Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer (2017) (47)
- The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. (2007) (46)
- Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. (2019) (46)
- Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. (2016) (45)
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. (2019) (45)
- Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC) (2019) (44)
- Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study (2018) (44)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2018) (44)
- Plasma ESR 1 Mutations and the Treatment of Estrogen Receptor – Positive Advanced Breast Cancer (2016) (43)
- Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) (2013) (43)
- Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. (2017) (42)
- PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (2019) (42)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
- Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial (2019) (41)
- Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. (2014) (40)
- Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis (2021) (39)
- A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. (2021) (37)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer (2020) (36)
- Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC) (2019) (36)
- Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells (2020) (36)
- Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial (2005) (36)
- Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. (2021) (36)
- Self-Supervised Nuclei Segmentation in Histopathological Images Using Attention (2020) (35)
- Abstract S1-03: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy (2016) (34)
- Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. (2013) (34)
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. (2021) (33)
- Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). (2019) (33)
- Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
- Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer (2020) (32)
- Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt? (2008) (32)
- Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (32)
- PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (2015) (31)
- Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial (2018) (31)
- Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (2019) (31)
- Mouse Models of Tumor Immunotherapy. (2016) (30)
- LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (30)
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. (2020) (30)
- Pertuzumab: new hope for patients with HER2-positive breast cancer. (2013) (30)
- The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. (2016) (29)
- Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66) (2013) (29)
- Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. (2019) (29)
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study (2019) (29)
- CD73: A potential biomarker for anti-PD-1 therapy (2015) (29)
- Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) (2018) (28)
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. (2019) (27)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
- Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial (2019) (27)
- Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer (2018) (27)
- Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors (2017) (27)
- A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer (2015) (26)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (26)
- The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. (2021) (26)
- Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. (2020) (25)
- Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). (2016) (24)
- Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. (2016) (24)
- Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (24)
- Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. (2012) (23)
- IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
- HER2-overexpressing breast cancer: time for the cure with less chemotherapy? (2011) (23)
- Activation of canonical BMP4-SMAD7 signaling suppresses breast cancer metastasis. (2020) (22)
- Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. (2015) (22)
- Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial. (2021) (21)
- Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. (2018) (21)
- Persistent Impairment in Cardiopulmonary Fitness following Breast Cancer Chemotherapy. (2019) (21)
- The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis (2018) (20)
- Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial (2018) (20)
- Molecular forecasting of breast cancer: time to move forward with clinical testing. (2006) (20)
- Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2020) (19)
- Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 (2020) (18)
- Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE (2013) (18)
- A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. (2020) (18)
- Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain (2019) (18)
- Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (2019) (17)
- Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. (2016) (17)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (17)
- Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. (2011) (17)
- Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene (2014) (17)
- Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022) (16)
- Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). (2021) (16)
- INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer (2021) (16)
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up (2021) (15)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (15)
- Advancing Immunotherapy in Metastatic Breast Cancer (2017) (15)
- 351OGENOMIC AND IMMUNE CHARACTERIZATION OF METASTATIC BREAST CANCER (MBC): AND ANCILLARY STUDY OF THE SAFIR01 & MOSCATO TRIALS. (2014) (15)
- Abstract PD5-05: Neratinib forERBB2mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial (2016) (15)
- Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study (2017) (15)
- Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 (2017) (15)
- Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring (2005) (15)
- PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (2017) (14)
- Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). (2006) (14)
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis (2018) (14)
- Abstract PD2-08: Neratinib + fulvestrant inERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial (2017) (14)
- Identification of an excellent prognosis subset of human papillomavirus associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (14)
- Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant. (2018) (14)
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial (2022) (14)
- Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. (2019) (14)
- Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? (2012) (13)
- 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group (2020) (13)
- Challenges in breast cancer clinical trial design in the postgenomic era (2004) (13)
- Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer (2020) (13)
- 296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial (2020) (13)
- Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I (2018) (13)
- Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 (2019) (13)
- Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study (2020) (12)
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). (2020) (12)
- Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics (2021) (12)
- The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. (2019) (12)
- A Meta-Analysis of Gene Expression Profiling Studies Identifies Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer. (2009) (12)
- Molecular comparison of interval and screen‐detected breast cancers (2019) (12)
- Breast cancer gene expression profiling: clinical trial and practice implications. (2005) (12)
- Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies (2013) (12)
- Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. (2019) (11)
- Securing the future of the clinician-scientist (2020) (11)
- Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy (2019) (11)
- Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial (2018) (11)
- High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers (2017) (11)
- Glomerulosclerosis: A paraneoplastic phenomenon? (2004) (11)
- Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. (2014) (11)
- Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (2021) (11)
- Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (2021) (11)
- Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial. (2021) (11)
- Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy (2022) (11)
- Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. (2019) (11)
- Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial (2015) (11)
- Gene profiling assay and application: the predictive role in primary therapy. (2011) (11)
- Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) (2016) (10)
- Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis (2018) (10)
- PIK 3 CA Genotype and a PIK 3 CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2012) (10)
- IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2018) (10)
- Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. (2015) (10)
- Tumor PIK 3 CA Genotype and Prognosis in Early-Stage Breast Cancer : A Pooled Analysis of Individual Patient Data (2018) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape (2016) (10)
- Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. (2011) (10)
- Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) (2017) (10)
- Faculty Opinions recommendation of Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. (2019) (10)
- Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients– the BReast cancer EXercise InTervention (BREXIT) trial protocol (2020) (9)
- Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2019) (9)
- Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy (2019) (9)
- Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. (2016) (9)
- Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. (2021) (9)
- Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). (2021) (9)
- Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3. (2018) (9)
- Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. (2014) (8)
- Computational Intelligence in Clinical Oncology: Lessons Learned from an Analysis of a Clinical Study (2008) (8)
- Abstract OT-03-05: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) (2021) (8)
- Genomic and molecular classification of breast cancer (2006) (8)
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in breast cancer (2010) (8)
- A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. (2020) (8)
- Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer (2021) (8)
- 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors (2021) (8)
- Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial (2019) (8)
- Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial. (2019) (8)
- ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. (2019) (8)
- Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer (2016) (7)
- Better characterisation of estrogen receptor (ER) positive luminal subtypes using genomic grade (2005) (7)
- Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. (2021) (7)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (7)
- KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. (2019) (7)
- Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis (2016) (7)
- On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. (2019) (7)
- Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (2020) (7)
- TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer (2006) (7)
- PTPN2 elicits cell autonomous and non–cell autonomous effects on antitumor immunity in triple-negative breast cancer (2022) (7)
- Abstract PD3-06: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial (2019) (7)
- Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice (2022) (7)
- Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. (2014) (7)
- Novel Targeted Agents and Immunotherapy in Breast Cancer. (2017) (7)
- Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 (2021) (7)
- Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC) (2015) (6)
- Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers (2021) (6)
- Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors. (2005) (6)
- Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies (2019) (6)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2018) (6)
- Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better? (2016) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy (2004) (6)
- Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC) (2022) (6)
- Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE" (2017) (6)
- Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2018) (5)
- Immunology and Immunotherapy of Breast Cancer (2015) (5)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) (5)
- Faculty Opinions recommendation of Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. (2019) (5)
- Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. (2022) (5)
- Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update (2021) (5)
- Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. (2022) (5)
- Gene expression profiling in breast cancer challenges the existence of intermediate histological grade (2005) (5)
- Better characterization of estrogen receptor (ER) positive luminal subtypes of breast cancer using genomic grade. (2005) (5)
- Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. (2022) (5)
- FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor. (2017) (5)
- Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). (2019) (5)
- Abstract S1-10: Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study (2017) (5)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. (2021) (5)
- Gene Expression Analysis: Current Methods (2016) (5)
- Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2018) (5)
- Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis (2021) (5)
- Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (2011) (4)
- A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol (2021) (4)
- Abstract PS10-04: Tucatinib favourably modulates the immune microenvironment and synergises with anti-PD1 therapy in a trastuzumab resistant HER2+ murine model (2021) (4)
- Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial (2020) (4)
- 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer (2020) (4)
- Review of: Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen (2008) (4)
- Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy (2019) (4)
- Faculty Opinions recommendation of Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. (2019) (4)
- Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial (2019) (4)
- Abstract OT1-03-03: FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplIfied oestrogeN rEceptor poSitive metaStatic breast cancEr (2016) (4)
- Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). (2021) (4)
- 329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer (2021) (4)
- Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (2022) (4)
- Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer (2019) (4)
- 355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) (2020) (4)
- Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial (2017) (4)
- FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer. (2014) (4)
- Limited Clinical Utility of Prognostic Gene Expression Profiles in Grade 3 Node-Negative Early Stage Breast Cancer. (2009) (4)
- Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy (2013) (4)
- Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. (2017) (3)
- Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. (2022) (3)
- Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer (2021) (3)
- Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC). (2018) (3)
- Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022) (3)
- Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (3)
- Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer (2016) (3)
- Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. (2022) (3)
- 14O_PR Biology of Breast Cancer Diagnosed in Young Women: Pooled Gene Expression Analysis From 3522 Patients (2012) (3)
- Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3. (2017) (3)
- Metastatic Breast Cancer: TIL it is Too Late (2019) (3)
- Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status (2021) (3)
- 323TiPEarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) (2017) (3)
- Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis (2013) (3)
- Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries (2019) (3)
- Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. (2022) (3)
- Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results (2005) (3)
- Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker? (2015) (3)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2019) (2)
- Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (2018) (2)
- Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer (2017) (2)
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). (2019) (2)
- Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. (2010) (2)
- Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies (2017) (2)
- Fulvestrant--ready to start its journey in the breast cancer adjuvant endocrine world? (2005) (2)
- Novel Targeted Agents and Immunotherapy in Breast Cancer. (2017) (2)
- Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. (2010) (2)
- Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial (2021) (2)
- Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2‐positive metastatic breast cancer: An Australian case series (2019) (2)
- Time to move forward from “first-generation” prognostic gene signatures in early breast cancer (2011) (2)
- Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials (2022) (2)
- Gene modules and pathological complete response to neoadjuvant chemotherapy in breast cancer. A pooled analysis. (2012) (2)
- Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions (2022) (2)
- 22P BCL2 Negative Breast Tumors but not Axillary Lymph Nodes Predict a Better Overall Survival in Patients Treated with Higher Doses of Epirubicin at a Median follow-up of 15.6 Years (2012) (2)
- Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen (2005) (2)
- Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial (2021) (2)
- Molecular characterization of early-stage her2-overexpressing breast cancer (her2+ bc) treated with adjuvant trastuzumab: identification of prognostic groups (2012) (2)
- ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. (2022) (2)
- Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling. (2011) (2)
- Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". (2019) (2)
- Abstract P1-08-02: Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement (2018) (2)
- Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays (2018) (2)
- 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia (2020) (2)
- Faculty Opinions recommendation of Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. (2019) (2)
- Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). (2015) (2)
- Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. (2020) (2)
- 349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) (2)
- Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (2016) (2)
- 202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy (2021) (2)
- Immune targeting in breast cancer: in whom and with what? (2015) (2)
- Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study. (2022) (2)
- In reply [3] (2007) (2)
- Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers (2023) (2)
- Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer (2021) (2)
- 91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial (2022) (2)
- Abstract PS5-03: Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial (2021) (2)
- MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases (2019) (2)
- Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumor suppressor in breast cancer (2016) (2)
- 126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2021) (2)
- Immunity and HER2-positive disease: never stop questioning. (2015) (2)
- Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial (2023) (2)
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study (2022) (2)
- Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival (2015) (2)
- 275P A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc) (2021) (2)
- Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). (2022) (2)
- Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. (2009) (2)
- Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib (2022) (1)
- Abstract OT2-01-01: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (2020) (1)
- Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations. (2013) (1)
- PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer (2013) (1)
- Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology (2019) (1)
- Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2–breast cancer (2019) (1)
- Highlights from the literature (1962) (1)
- Abstract P4-13-01: PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy—confirmed efficacy and safety (2016) (1)
- Investigating the role of tumor-infiltrating lymphocytes in advanced HER2-positive breast cancer. (2017) (1)
- persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). (2021) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- Checkpoint blockade in the treatment of breast cancer: current status and future directions (2018) (1)
- RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy (2015) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2020) (1)
- Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients– the BReast cancer EXercise InTervention (BREXIT) trial protocol (2020) (1)
- Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen (2005) (1)
- Identification of potential therapeutic targets in estrogen receptor-positive breast cancer by gene expression profiling (2007) (1)
- 136MO Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study (2022) (1)
- 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB) (2020) (1)
- KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer (2019) (1)
- Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2019) (1)
- Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials (2022) (1)
- Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma (2005) (1)
- 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL (2020) (1)
- OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC (2019) (1)
- Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer. (2012) (1)
- Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial (2018) (1)
- Around the world and back again (2019) (1)
- Abstract A72: The E3-ligase E6AP represses breast cancer metastasis through regulation of ECT2-Rho-GTPases signaling (2016) (1)
- Abstract CT135: Uncovering the genomic heterogeneity of multifocal breast cancer (2015) (1)
- Abstract P2-09-06: Safety and efficacy of stereotactic body radiotherapy and Pembrolizumab in advanced breast cancer patients with 1 to 5 metastases (2019) (1)
- Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL (2020) (1)
- Abstract LB-069: ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer; analysis of 521 patients in the SoFEA and PALOMA3 trials (2016) (1)
- The RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma (2018) (1)
- Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India (2021) (1)
- PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data (2014) (1)
- Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study (2020) (1)
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (1)
- Abstract IA16: Clinical relevance of host immunity in breast cancer (2016) (1)
- Faculty Opinions recommendation of Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. (2019) (1)
- Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2021) (1)
- Faculty Opinions recommendation of nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. (2019) (1)
- Faculty Opinions recommendation of Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. (2019) (1)
- Abstract P6-18-03: Biomarker analysis of CDK 4/6 and endocrine pathways in hormone-receptor positive (HR+) advanced breast cancer (ABC) bone only disease patients: A joint analysis of PALOMA-2 and PALOMA-3 studies (2019) (1)
- Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis (2019) (1)
- Faculty Opinions recommendation of Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. (2019) (1)
- Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome (2012) (1)
- Fine-tuning chemotherapy in the era of dual HER2 targeting. (2018) (1)
- Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial (2019) (1)
- Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer (2021) (1)
- 353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer (2020) (1)
- Abstract P5-11-07: Real-world predictors of first-line treatment and descriptive outcomes in HR+/HER2−metastatic breast cancer patients in the US (2020) (1)
- Abstract P5-04-18: Unfavourable tumour stromal immune cell infiltrates but not circulating immune cell profiles in Aboriginal women with breast cancer (2020) (1)
- Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (2022) (1)
- Abstract PD10-02: A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial) (2022) (1)
- Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data (2014) (1)
- Abstract P1-19-16: Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2–negative advanced breast cancer: An updated analysis (2020) (1)
- PIK3CA mutation-associated gene expression signature correlates with deactivation of the PI3K pathway and predicts benefit to endocrine therapy in high-risk ER+ (luminal B) breast cancers (BC). (2009) (1)
- Investigating tamoxifen resistance in the luminal B estrogen receptor positive breast cancer subtype: Tailoring treatment in hormone responsive breast cancer (2007) (1)
- Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review. (2020) (1)
- An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (1)
- Abstract P3-08-15: Immunologic correlates of long-term outcome in the residual disease of triple-negative breast cancer after neoadjuvant chemotherapy (2020) (1)
- 276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC) (2022) (1)
- Faculty Opinions recommendation of Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. (2019) (1)
- Brocade: The National Breast Cancer Foundation Repository of Primary Tumours and Metastases from Breast Cancer Patients (2017) (1)
- Faculty Opinions recommendation of Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. (2019) (1)
- PIK3CA, AKT1 MUTATION AND HER2 AMPLIFICATION GENE SIGNATURES (GS) SUGGEST PREDOMINANTLY NEGATIVE FEEDBACK INHIBITION OF PI3K/AKT PATHWAY IN HUMAN BREAST CANCER (BC). (2009) (1)
- In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. (2018) (1)
- P2-18-01: The Magnitude of Trastuzumab Benefit in HER2−Positive (HER2+) Lobular Breast Carcinoma (BC): Results of a HERA Trial Sub-Group Analysis. (2011) (0)
- 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
- Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2 (2018) (0)
- Abstract P2-04-16: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition (2017) (0)
- Abstract PD3-1: Evaluation and clinical impact of intra-tumor heterogeneity (ITH) in primary HER2-overexpressing breast cancers (HER2+BC) treated with adjuvant trastuzumab and chemotherapy (CT) (2015) (0)
- Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. (2019) (0)
- PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer (2022) (0)
- Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis (2018) (0)
- 12INMODULATION OF IMMUNE RESPONSE IN BREAST CANCER AND CLINICAL IMPLICATIONS. (2014) (0)
- 18 The Neo BIG programme (2010) (0)
- Vision and collaboration: essential ingredients for the future of breast cancer research. Editorial overview (2004) (0)
- 164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355 (2022) (0)
- Abstract P6-10-02: MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates (2017) (0)
- 67TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2020) (0)
- Abstract IA20: Targeting the immune microenvironment in breast cancer (2019) (0)
- Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. (2023) (0)
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) (0)
- Edinburgh Research Explorer PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer (2018) (0)
- Advances in breast cancer translational research (2012) (0)
- A21A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer (2015) (0)
- # 3016 - Definition of Clinically Distinct Subtypes Within Estrogen Receptor Positive Luminal Breast Carcinomas (2005) (0)
- 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa (2022) (0)
- Genome editing provides solution for cell therapy safety and immune tolerance : a guide for a One 4 All pluripotent cell line (2018) (0)
- Abstract P5-02-16: SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2- breast cancer (2023) (0)
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis (2011) (0)
- Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy. (2022) (0)
- Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2022) (0)
- Molecular segmentation of luminal breast: Reality in 2015? (2015) (0)
- Faculty Opinions recommendation of Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). (2019) (0)
- IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC (2019) (0)
- Effect Of Exercise Training During Anthracycline Chemotherapy For Breast Cancer On Skeletal Muscle Composition, Strength And Physical Function. (2020) (0)
- Abstract P2-03-06: Genomic characterization of 992 primary breast cancers (2017) (0)
- Reply (2005) (0)
- Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial (2020) (0)
- Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT. (2022) (0)
- Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials? (2022) (0)
- Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. (2022) (0)
- Abstract ES6-3: Immunotherapy vs Capecitabine for Triple Negative Breast Cancer (2022) (0)
- Immunotherapy Approaches for Breast Cancer Patients in 2023. (2023) (0)
- Faculty Opinions recommendation of A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. (2019) (0)
- Mechanism of resistance to chemotherapy in triple negative breast cancer (2017) (0)
- Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545 (2020) (0)
- Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. (2023) (0)
- Targeting immune pathways in breast cancer (2019) (0)
- Immuno-oncology treatment in early stage TNBC (2021) (0)
- Abstract OT2-04-03: Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer (2019) (0)
- Role of cardiac reserve as a tool to unmask cardiotoxicity following anthracycline therapy and whether exercise training can attenuate cardiotoxicity. (2018) (0)
- Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer. (2022) (0)
- Continuous inappropriate use of serum tumour markers. Authors' reply (2005) (0)
- Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
- 559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial (2022) (0)
- 370 Suppression of Breast Cancer Metastasis by BMP4 (2012) (0)
- Evaluation of PI3K-pathway–activation status in matched primary (P) and metastatic (M) ER+/HER2- breast cancer (BC) lesions according to PIK3CA-mutation status. (2014) (0)
- The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer. (2004) (0)
- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer (2022) (0)
- Abstract 3541: CD4+ T cells infiltrating human breast cancer are critical for an effective anti-tumor immune response (2012) (0)
- Differential Expression of the Na+/I- Symporter by Endocrine Receptor Status: A Potential New Therapeutic Target in Estrogen Receptor Negative High Grade Breast Cancers (2015) (0)
- Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis. (2014) (0)
- Abstract IA31: What limits the response of breast cancer to immunotherapy? (2018) (0)
- Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. (2021) (0)
- Abstract PD9-07: Role of immunosuppressive JNK pathway in the tumor microenvironment among Triple Negative Breast Cancer subtypes in IBCSG Trial 22-00 (2023) (0)
- Efficacy of neratinib neoadjuvant therapy in a pre-clinical model of HER2( ve) breast cancer brain metastasis (2019) (0)
- Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO (2022) (0)
- TILs Predict Response to Trastuzumab in Early Breast Cancer (2014) (0)
- [P2-09-01] T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial (2018) (0)
- Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial (2019) (0)
- The next big questions in cancer research (2023) (0)
- Gene Expression Analaysis of Tamoxifen Resistance in Breast Cancer (2006) (0)
- 729 Exercise Training Attenuates Anthracycline-Induced Myocardial Injury in Early-Stage Breast Cancer Patients (2020) (0)
- Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer (2019) (0)
- An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer (2022) (0)
- Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
- Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression (2005) (0)
- Abstract PD2-09: The role of CYP2D6 mediated tamoxifen metabolism in the suppression of ovarian function trial (SOFT) (2021) (0)
- PD03-10: Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis. (2011) (0)
- Abstract P6-05-12: Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations (2013) (0)
- Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) (2021) (0)
- Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. (2020) (0)
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022) (0)
- Gene expression profiling identifies potential therapeutic targets in estrogen receptor positive breast cancer (2007) (0)
- 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) (2020) (0)
- Abstract P6-01-01: RANK/RANKL expression by immunohistochemistry (IHC) in young breast cancer (BC) patients and during pregnancy: Association with clinicopathologic features, gene expression profiles and patient outcome (2015) (0)
- Abstract SP086: Rationale for combination therapies (2021) (0)
- Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 (2022) (0)
- Abstract P4-09-12: Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B (2023) (0)
- Abstract 1220:PIK3CAmutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
- Abstract P4-14-02: Analysis of DRFI and OS of HR-positive, HER2-negative breast cancer patients treated on the BIG1-98 study, classified according to a novel, integrated, clinical-pathologic and genomic classification method (2019) (0)
- Measurement methods for eliciting opinions on treatment benefits, toxicities and acceptable trade-offs of the two, within the PERSEPHONE trial (2017) (0)
- BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme. (2023) (0)
- An Effective Exercise Intervention Targeting Breast Cancer Patients at Greatest Risk of Cardiac Dysfunction (2018) (0)
- Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients withPIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC) (2021) (0)
- The impact of coding germline variants on contralateral breast cancer risk and survival (2023) (0)
- PI3K and/or MTOR Inhibitors: Current Status, Future Directions (2012) (0)
- 92OThe Breast International Group (BIG) AURORA pilot study for molecular screening in metastatic breast cancer (MBC) patients (2015) (0)
- Abstract PD5-03: Characterization of high TIL breast cancers reveals a prognostic and functionally distinct tissue-resident memory subpopulation (2019) (0)
- Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. (2022) (0)
- Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2019) (0)
- Faculty Opinions recommendation of Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2019) (0)
- P644Changes in cardiopulmonary fitness and cardiac reserve 12-months following anthracycline-based chemotherapy with or without concurrent exercise training (2018) (0)
- Pervasive chromosomal instability and karyotype order in tumour evolution (2020) (0)
- Exercise Training Attenuates Chemotherapy-Induced Systolic Dysfunction Measured by Novel Cardiac Magnetic Resonance-Derived Global Longitudinal Strain (2018) (0)
- Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial (2017) (0)
- Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs). (2022) (0)
- Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. (2012) (0)
- Abstract P1-01-09: BMP4 suppresses the progression of breast cancer through altered expression of metastasis regulating genes (2018) (0)
- Review of:Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen (2008) (0)
- Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer (2022) (0)
- CD4+ T cells infiltrating human breast carcinomas nucleate the immune response (2011) (0)
- Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER 1 Advanced Breast Cancer (2021) (0)
- Abstract P4-09-05: Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials (2023) (0)
- What's in a name? That which we call Immune Cells by any other name would all smell as sweet. (2022) (0)
- 399 Reduced End Systolic Volume is associated With Attenuated Cardiac Reserve and Lower Exercise Capacity in Women Recently Diagnosed With Breast Cancer (2020) (0)
- Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer (2023) (0)
- Early Assessment of Proliferation by the Genomic Grade Index (GGI) Predicts Response to Neo-Adjuvant Letrozole (2009) (0)
- A poor prognosis gene transcription signature associated with PIK3CA mutation in ER+ breast cancer (2007) (0)
- Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. (2023) (0)
- Effective incorporation of biospecimen collection for translational studies into a phase III trial: The NeoALTTO experience (BIG 01-06) (2013) (0)
- ESMO-EACR - Targeted therapies: Promises, successes and failures (2012) (0)
- Gene Expression Analysis: Applications (2016) (0)
- 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial (2022) (0)
- Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients (2023) (0)
- Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) (2023) (0)
- Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. (2022) (0)
- A novel framework for evaluating biomarker response relationships in immuno-oncology (IO). (2018) (0)
- Abstract P4-10-16: Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer (2020) (0)
- Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC) (2022) (0)
- 286 Anthracycline Chemotherapy is not associated with Reductions in Right-Ventricular or Left Atrial Strain in Early-Stage Breast Cancer Patients (2020) (0)
- Abstract 5408: CD73 as a target in cancer immunotherapy (2012) (0)
- Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients (2022) (0)
- Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC). (2022) (0)
- Faculty Opinions recommendation of Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. (2019) (0)
- Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC). (2018) (0)
- Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. (2015) (0)
- Abstract P5-08-01: Reconstructing the evolutionary paths of BIG 1-98 (2018) (0)
- Extended adjuvant aromatase inhibitor therapy: less is more. (2021) (0)
- Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. (2016) (0)
- TRANSBIG: The way forward in breast cancer research (2005) (0)
- Novel Therapies in Development for HER2-Amplified Breast Cancer (2017) (0)
- Native T1 Times Increase After 3 Months of Anthracycline-Based Chemotherapy for Breast Cancer (2018) (0)
- Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial (2021) (0)
- Faculty Opinions recommendation of Triple-negative breast cancers - a panoply of cancer types. (2019) (0)
- PIK3CA mutations in primary HER2-positive and triple negative breast cancer. (2013) (0)
- P643An effective exercise intervention targeting breast cancer patients at greatest risk of cardiac dysfunction (2018) (0)
- Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial (2020) (0)
- Faculty Opinions recommendation of Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. (2019) (0)
- Moving Towards new standards in the systemic treatment of post-menopausal non metastatic breast cancer (2005) (0)
- PG 3.03 Molecular segmentation in luminal breast cancer: how to select the driver pathways (2015) (0)
- 13 The role of gene expression profiling in early drug development (2010) (0)
- 2161 POSTER INTEGRATE: Driving Excellence in Integrative Cancer Research Through Innovative Biomedical Infrastructures (2011) (0)
- Faculty Opinions recommendation of Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness. (2019) (0)
- Abstract P5-04-03: Bone morphogenic protein-4: A novel metastasis suppressor gene in breast cancer (2013) (0)
- Reply to A. Ocaña et al and P.G. Tsoutsou et al. (2015) (0)
- Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. (2019) (0)
- Abstract OT2-07-08: Withdrawn (2019) (0)
- Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort (2023) (0)
- Is genomic grading killing histological grading (2006) (0)
- Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time? Reply (2015) (0)
- CD4+ T cells infiltrating human breast carcinomas are critical for an effective anti-tumor immune response (2012) (0)
- Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes (2023) (0)
- Molecular heterogeneity of luminal breast cancer (2011) (0)
- Cardiopulmonary Fitness and Cardiac Reserve 9 Months After the Completion of Anthracycline-Based Chemotherapy with or without Concurrent Exercise Training (2018) (0)
- Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study (2022) (0)
- Conference Scene: Advances in breast cancer translational research (2012) (0)
- Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab andnab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial (2021) (0)
- Abstract ES6-3: Tumor infiltrating lymphocytes in breast cancer (2015) (0)
- Circulating Tumor DNA in HER2-Ampli fi ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (2019) (0)
This paper list is powered by the following services:
Other Resources About Sherene Loi
What Schools Are Affiliated With Sherene Loi?
Sherene Loi is affiliated with the following schools:
- University of Texas Southwestern Medical Center
- Heidelberg University
- University of Calgary
- Institute of Cancer Research
- MD Anderson Cancer Center
- University of Sydney
- University of Oxford
- University of Melbourne
- University of California, Los Angeles
- Kiel University
- University of Valencia
- Humanitas University
- University of Western Australia
- Seoul National University
- Université libre de Bruxelles
- Tampere University
- University of Milan
- Queen Mary University of London
